Volt PFA System
ABBOTT MEDICAL · Decision date Oct 15, 2026
What did the FDA approve?
The FDA database entry records approval of a post-approval study protocol for the Volt PFA System (PMA P250022, supplement S002) under the Normal 180 Day Track with no user fee. The recorded purpose is to comply with conditions in the original approval order for P250022. The device category is a percutaneous cardiac ablation catheter for treatment of atrial fibrillation with irreversible electroporation, product code QZI, cardiovascular specialty, applicant Abbott Medical. The approval applies to the PAS protocol, not to the entire system.
The database shows the supplemental reason as Postapproval Study Protocol, but does not describe the study's design, endpoints, enrollment, or timeline, and provides no new safety or effectiveness findings. The statement's stated compliance purpose does not independently show that any condition has been met. Because the entry identifies the supplement as S002 of P250022, it is a supplement to that PMA rather than a separate original approval.
FDA approval order statement
approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250022
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 15, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250022/S002
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Oct 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Abbott Medical
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250022. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250022 · Original PMA
Volt PFA System
P250022/S002 received
Application receipt date recorded by FDA.
P250022/S009 · Related supplement
Volt PFA Catheter, Sensor Enabled
P250022/S012 · Related supplement
VOLT PFA CATHETER, SENSOR ENABLED
P250022/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Volt PFA SystemP250022 | ABBOTT MEDICAL | PMA approval | Dec 19, 2025 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
VOLT PFA CATHETER, SENSOR ENABLEDP250022/S012 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Sphere-9 Catheter and Affera Ablation SystemP240013/S028 | Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 5050 Nathan Ln. N., Plymouth, MN, 55442
Sources and methodology
- Original FDA record: P250022/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
